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BACKGROUND AND PURPOSE
The aim was to advance the understanding of Orai proteins and identify a speciﬁc inhibitor of the associated calcium entry
mechanism in vascular smooth muscle cells (VSMCs).
EXPERIMENTAL APPROACH
Proliferating VSMCs were cultured from human saphenous veins. Intracellular calcium was measured using fura-2, whole-cell
current was recorded using patch-clamp and cell migration quantiﬁed in modiﬁed Boyden chambers. Subcellular protein
localization was determined by microscopy. Isometric tension was recorded from mouse aortic rings.
KEY RESULTS
Molecular disruption and rescue experiments indicated the importance of Orai1 in calcium entry caused by store depletion
evoked passively or by platelet-derived growth factor (PDGF), suggesting the presence of Ca2+ release-activated Ca2+ (CRAC)
channels like those of the immune system. The CRAC channel blocker, S66, was a potent inhibitor of the VSMC signals, IC50
26 nM, which was almost two orders of magnitude greater than with leucocytes. S66 had no effect on PDGF- and ATP-
evoked calcium release, overexpressed transient receptor potential canonical (TRPC)5 channels, native TRPC1/5-containing
channels, stromal interaction molecule 1 clustering, non-selective cationic current evoked by store depletion and
phenylephrine-evoked aortic contraction. S66 reduced PDGF-evoked VSMC migration while having only modest effects on cell
proliferation and no effect on cell viability.
CONCLUSIONS AND IMPLICATIONS
The data suggest that Orai1 has a role in human VSMC migration, and that a CRAC channel inhibitor has high potency and
selectivity for the associated calcium entry, suggesting a distinct characteristic of vascular CRAC channels and the potential for
selective chemical suppression of vascular remodelling.
Abbreviations
CRAC channel, Ca2+ release activated Ca2+ channel; PDGF, platelet-derived growth factor; PGPC, 1-palmitoyl-2-glutaroyl-
phosphatidylcholine; siRNA, short interfering RNA; STIM1, stromal interaction molecule 1; S66, 3-ﬂuoropyridine-4-
carboxylic acid (2′,5′–dimethoxybiphenyl-4-yl)amide; TRPC, transient receptor potential canonical; VSMC, vascular
smooth muscle cell
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Contractile smooth muscle cells regulate the diameters of
most blood vessels. Although they are relatively quiescent,
throughout life they retain capacity for profound but con-
trolled plasticity that enables them to change reversibly to
non-contractile and mobile phenotypes that play critical
roles in vascular development, tissue remodelling and
responses to injury (Owens et al., 2004). This property of
these cells contributes not only to physiology but to major
disease phenomena and unwanted clinical responses, which
include restenosis, atherosclerosis and neointimal hyperpla-
sia of the saphenous vein (Angelini and Jeremy, 2002; Kumar
et al., 2006). The molecular events controlling phenotypic
switching in smooth muscle cells and the properties of the
non-contractile cells, such as mobility, are starting to emerge
(Owens et al., 2004).
Important events determining smooth muscle cell func-
tions are plasma membrane ion ﬂuxes such as Ca
2+ entry
(Beech, 2007). Voltage-gated Ca
2+ entry channels (especially
the dihydropyridine-sensitive L-type channels) have estab-
lished roles in the regulation of blood pressure and the treat-
ment of hypertension. However, other non-voltage-gated
Ca
2+ entry mechanisms exist and appear to make greater
contributions in the non-contractile smooth muscle cells
(Landsberg and Yuan, 2004; Beech, 2007). One of these
mechanisms is store-operated Ca
2+ entry, which was identi-
ﬁed in vascular smooth muscle 30 years ago (Casteels and
Droogmans, 1981). Various studies have suggested roles of
transient receptor potential canonical (TRPC) channels (Alex-
ander et al., 2008) in the store-operated mechanism and
shown the channels to have an important role in non-
contractile properties of smooth muscle cells (Sweeney et al.,
2002; Kumar et al., 2006; Takahashi et al., 2007; Li et al.,
2008). Nevertheless, experiments using TRPC channel block-
ers or molecular approaches for TRPC disruption suggest that
TRPC channels explain only part of the store-operated Ca
2+
entry signal of vascular smooth muscles (VSMCs) (Li et al.,
2008) or even none of it according to some studies (Potier
et al., 2009). Therefore, an additional mechanism is inferred.
A candidate for the additional mechanism is the store-
operated Ca
2+ release-activated Ca
2+ (CRAC) channel that has
been associated primarily with immune cells (Hogan et al.,
2010).
Determinants of CRAC channels are stromal interaction
molecule 1 (STIM1) and Orai1 (Feske et al., 2006; Cahalan,
2009; Hogan et al., 2010). Orai1 is one of three related
mammalian proteins encoded by distinct genes. The pro-
teins are thought to contain four membrane-spanning
segments and resemble, in some regards, the extensively-
studied tetraspanin proteins, which have roles in mamma-
lian cell morphology and motility. Tetraspanins had not
been considered to be ion channel subunits, but various
studies now suggest that Orai1 is the ion pore-forming
subunit of CRAC channels (Hogan et al., 2010). Despite the
focus on immune cells and absence of a vascular phenotype
in patients with disrupted Orai1, reports have suggested
that Orai proteins are expressed, and that Orai1 is func-
tional in VSMCs (Berra-Romani et al., 2008; Baryshnikov
et al., 2009; Potier et al., 2009; Bisaillon et al., 2010; Ng
et al., 2010). One report has importantly described a whole-
cell CRAC channel-like current in rat cultured VSMCs
(Potier et al., 2009), but the very small size of the current
and failure to detect the current in the presence of physi-
ological Ca
2+ have generated challenges for establishing its
relevance to VSMC biology. Here we describe an investiga-
tion of the relevance of Orai proteins and CRAC channels
to proliferating human saphenous vein VSMCs with particu-
lar focus on identiﬁcation of a chemical agent that could
facilitate studies of the mechanism in the cardiovascular
ﬁeld.
Methods
Cell culture
Freshly discarded human saphenous vein segments were
obtained anonymously and with informed consent from
patients undergoing open heart surgery in the General Inﬁr-
mary at Leeds. Approval was granted by the Leeds Teaching
Hospitals Local Research Ethics Committee. Proliferating
VSMCs were prepared using an explant technique (Porter
et al., 2001) and grown in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) supplemented with 10% fetal calf serum
(FCS), penicillin/streptomycin and L-glutamine at 37°C in a
5% CO2 incubator. Experiments were performed on VSMCs
passaged two to ﬁve times; all of the cells stained positively
for smooth muscle a-actin and smooth muscle myosin heavy
chain and were non-contractile. Tetracycline-induced expres-
sion of exogenous human TRPC5 in HEK 293 cells has been
described previously (Zeng et al., 2004). HL-60 (human
promyelocytic leukaemia) cells were from ATTC (Teddington,
Middlesex, UK) and were cultured in RPMI 1640 with 10%
FCS and penicillin/streptomycin.
VSMC transfections and
knock-down validation
Cells (0.5–2 ¥ 10
6) were centrifuged (100¥ g) for 10 min,
resuspended in Basic Nucleofector solution (Amaxa GmbH,
Lonza GmbH, Cologne, Germany), mixed with 1 mM short
interfering (si) RNA (Ambion Europe Ltd, Applied Biosystems,
Warrington, UK; Table S1) and transferred into a cuvette for
electroporation (Amaxa). With this method, the siRNA con-
centration is higher than used with lipid transfection
methods, but the exposure time to the siRNA is considerably
shorter. The scrambled control siRNA was Silencer Negative
Control #1, which is a 19 bp scrambled sequence with no
signiﬁcant homology to human gene sequences (Ambion).
Cells were transferred from cuvettes to pre-warmed culture
medium and incubated in a 5% CO2 incubator at 37°C.
Culture medium was changed after 24 h, and measurements
were made after a further 24 h. When two siRNA probes were
used as a cocktail, each probe was used at one-half of its usual
concentration. Full-length cDNA for Orai1 (BC013386) was
purchased from Geneservice (Source Bioscience LifeSciences,
UK) and subcloned into pcDNA6/V5-His (Invitrogen, Paisley,
UK) at EcoRI/XhoI sites. cDNA encoding eYFP-STIM1 was a
gift from T Meyer. Clones were sequenced to conﬁrm identi-
ties. Transfections with 1–1.5 mg of DNA also occurred by
electroporation.
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transcription PCR
Total RNA was extracted from saphenous vein smooth muscle
cells using a Tri-reagent protocol followed by DNase I
(Ambion) treatment (Fountain et al., 2004). One microgram
of total RNA was used for RT based on oligo-dT primers and
AMV RT enzyme. The speciﬁcity of PCR was veriﬁed by reac-
tions without RT (–RT) and by melt curve analysis of PCR
products. Sequences of PCR primers are shown in Table S1.
PCR products were electrophoresed on 2% agarose gels con-
taining ethidium bromide. No PCR products occurred in the
absence of RT. With RT, there was only a single product of the
correct size, giving a single peak in the melt curve. All PCR
products were sequenced to conﬁrm identity (Lark Technolo-
gies,Takeley, Essex, UK). Real-time PCR was carried out using
a Lightcycler (Roche, Welwyn Garden City, UK) largely as
described previously (Fountain et al., 2004). Relative abun-
dance of target RNA was normalized to b-actin RNA, which
showed no difference between samples. PCR efﬁciency (E)
was 10
(-1/slope). Relative abundance of target RNA was calcu-
lated from (Eb-actin
Cp)/( Etarget
Cp), where PCR cycle crossing
points (CP) were determined by ﬁt-points methodology. PCR
reactions were at least in duplicate.
Western blotting
Cells were collected using 1 mL of ice-cold phosphate-
buffered saline (PBS) and pelleted at 4°C and then lysed in
Laemmli sample buffer supplemented with complete protease
inhibitor cocktail (Roche). The lysate was centrifuged to
remove particulate matter, and equal amounts of protein were
separated by 8% sodium dodecyl sulphate polyacrylamide gel
electrophoresis and transferred onto nitrocellulose mem-
brane. Membranes were incubated with blocking buffer (con-
taining 0.1% Tween 20 and 5% nonfat dry milk) for 2 h at
room temperature, followed by incubation in dialysed rabbit
anti-Orai1 antibody (Alomone Labs Ltd., Jerusalem, Israel,
#ACC-060) overnight at 4°C. Anti-b-actin antibody (1:1000)
was from Santa Cruz. Membranes (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) were then washed and incubated
with secondary antibody. Labelling was detected using Super-
Signal West Pico chemiluminescent substrates (Pierce,
Thermo FisherScientiﬁc Inc., Rockford, IL, USA).
Intracellular calcium measurements
Cells were pre-incubated with fura-2AM for 1 h at 37°C fol-
lowed by a 0.5 h wash at room temperature. HL-60 cells were
centrifuged in the plate at 2 ¥ 10
5 cells per well. Measure-
ments were made at room temperature on a 96-well plate
reader (FlexStation, Molecular Devices Inc., Sunnyvale, CA,
USA). The change (D) in intracellular calcium (Ca
2+
i) concen-
tration is indicated as the ratio of fura-2 emission intensities
for 340 and 380 nm excitation (F ratio). Wells within
columns of the 96-well plate were loaded alternately for test
and control conditions. The recording solution contained
(mM): 130 NaCl, 5 KCl, 8 D-glucose, 10 HEPES and 1.2 MgCl2,
titrated to pH 7.4 with NaOH. When indicated, 0.2 or 1.5 mM
CaCl2 was added. EGTA was not included in the Ca
2+-free
recording solution because of the solution addition, rather
than replacement, format of the FlexStation; therefore, con-
taminating Ca
2+ was present (estimated to be 1–10 mM).
Deconvolution microscopy
VSMCs, 48 h post-transfection, were detached and trans-
ferred to glass coverslips with fresh culture medium and
allowed to spread for 24 h. After treatments with reagents,
the cells were ﬁxed in methanol for 10 min at -20°C, washed
and rehydrated in PBS, and mounted onto glass slides using
ProLong Gold anti-fade (Molecular Probes
®, Invitrogen,
Paisley, UK). Cells were visualized on an Olympus IX-70
inverted microscope using a ¥ 100 UPLAN objective (NA 1.35)
supported by a DeltaVision deconvolution system (Applied
Precision LLC Issaquah, WA, USA) with SoftWoRx image
acquisition and analysis software. Images were captured on a
Roper CoolSNAP HQ CCD camera, and epiﬂuorescence was
recorded using ﬁlter sets for FITC. Wide-ﬁeld optical sections
of 0.2 mm were acquired throughout the z plane of the cells
and deconvolved using a constrained iterative algorithm
assigned by Delta Vision.
Cell assays
Cell migration assays were performed in duplicate in modiﬁed
Boyden chambers with polycarbonate membranes containing
8 mm pores (BD Biosciences, Oxford Science Park, Oxford,
UK). Cells in suspension (1 ¥ 10
5) were loaded in the upper
chamber in DMEM supplemented with 0.4% FCS. The lower
chamber contained DMEM (0.4% FCS) supplemented with
the chemoattractant 10 ng mL
-1 platelet-derived growth
factor (PDGF)-BB (Invitrogen). After 8 h at 37°C in a 5% CO2
incubator, cells that had attached but not migrated were
scraped from the upper surface, membranes were ﬁxed in 70%
ethanol at -20°C and the migrated cells were stained with
haematoxylin and eosin and evaluated by counting cell nuclei
in 10 randomly chosen ﬁelds under light microscopy. For
Orai1 knock-down cell proliferation experiments, equal
numbers of cells from the same patient were transfected and
seeded in parallel into six-well tissue culture plates in DMEM
culture medium plus 10% FCS. Medium was changed after
24 h, and cells were incubated for a further 24 h. Cells were
collected after trypsinization, stained with trypan blue, and
the cell number was determined in duplicate wells and
counted at least twice with a haemocytometer. Trypsinized
wells were observed microscopically to conﬁrm that all cells
had been released. For S66 experiments, cells at 40–50% con-
ﬂuence were seeded in 96-well plates for the indicated time
periods in at least triplicate wells. At the end of the speciﬁed
times, cells were ﬁxed and stained with haematoxylin and
eosin for counting in four random ﬁelds. The medium was
replaced every 24 h to provide fresh S66.
Patch-clamp recordings
Recordings were made using the Patchliner planar patch-
clamp system (Nanion Technologies, Munich, Germany) in
whole-cell mode (Milligan et al., 2009). Prior to recordings,
cells were detached from culture ﬂasks with Detachin (Gelan-
tis Inc., AMS Biotechnology Europe Ltd., Abingdon, UK, cat.
no. T100110) or 0.05% Trypsin/EDTA and resuspended at a
density of 1 ¥ 10
6–5 ¥ 10
7 mL
-1 in extracellular solution that
was the same as the recording solution for Ca
2+ measurements
except it contained 0.2 mM CaCl2 and 100 mM niﬂumic acid.
The intracellular recording solution contained (mM): 40
EGTA, 17 CaCl2, 2 MgCl2, 8 NaCl, 1 Na2ATP, 10 HEPES, 66 L-
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culated unbound Ca
2+, 100 nM). Corrections were not made
for liquid–liquid junction potentials. Voltage ramps were
applied from -100 to +100 mV for 1 s every 10 s from a
holding potential of 0 mV. Currents were ﬁltered at 1 kHz
and sampled at 3 kHz.
Isometric tension recording
For isometric tension recordings, 8 week old male C57/BL6
mice were killed by CO2 asphyxiation and cervical dissocia-
tion in accordance with Schedule 1 Code of Practice, UK
Animals Scientiﬁc Procedures Act 1986. The thoracic aorta of
the mouse was removed and placed in ice-cold Hank’s solu-
tion. Fat was removed by dissection, and blood was ﬂushed
from the lumen with Hank’s solution. Hanks solution con-
tained (mM): NaCl, 137; KCl, 5.4; CaCl2, 0.01; NaH2PO4, 0.34;
K2HPO4, 0.44; D-glucose, 8; HEPES, 5. Vessels were mounted
on two 40 mm diameter wires for isometric tension recording
in a 410A dual wire myograph system (Danish Myo Technol-
ogy, Aarhus, Denmark). The wires were separated by 1 mm to
provide basal tension, and the bath solution was at 37°C
gassed continuously with 95% O2 and 5% CO2. The bath
solution contained (mM): 125 NaCl, 3.8 KCl, 25 NaHCO3, 1.5
MgSO4, 1.2 KH2PO4,8D-glucose, 1.2 CaCl2, 0.02 EDTA. For
Ca
2+-free solution (0 Ca
2+), Ca
2+ was omitted.
Reagents
S66 [3-ﬂuoropyridine-4-carboxylic acid (2′,5′’-
dimethoxybiphenyl-4-yl)amide] was a gift from GSK
(Oxbridge, Middlesex, UK) (GSK1349571A); its chemical
identity was conﬁrmed independently by liquid chromatog-
raphy mass spectrometry analysis (Leeds). S66 is an abbrevia-
tion of ‘Synta 66’ from patent WO 2005/009954 (Ng et al.,
2008; Di Sabatino et al., 2009). All other reagents were from
Sigma (Sigma-Aldrich, Gillingham, Dorset, UK) unless indi-
cated otherwise.
Data analysis
Mean data are presented as mean  SEM, where n represents
the number of independent experiments and N represents the
number of wells of a 96-well plate used in a single experiment.
For patch-clamp experiments, n was the number of recordings
from individual cells. In all experiments, comparisons were
made independently with cells from at least three patient
samples. Experiments were all performed in test and control
pairs, and so t-tests were used for comparisons. Each experi-
ment had its own paired control (ctrl), even though only
single control columns (white) are shown in the ﬁgures.
*P-values <0.05, which were taken to indicate signiﬁcant dif-
ference; no signiﬁcant difference is indicated by NS. Data were
analysed and presented, and curves were ﬁtted using Origin
software (OriginLab Corporation, Northampton, MA, USA).
Results
Orai1 function in Ca
2+ entry evoked by
store depletion in proliferating human
saphenous VSMCs
Messenger RNAs encoded by the Orai genes were readily
detected in proliferating VSMCs and had relatively high
abundance (Figure S1). To investigate if the gene expression is
functionally relevant, we measured the Ca
2+ entry signal
occurring when Ca
2+ was added back to cells that had been
store-depleted by the pharmacological agent thapsigargin
(Figure S2). Speciﬁc knock down of expression was achieved
using small interfering (si) RNAs (Figure S3 and S4, Table S1).
Knock down of Orai1 by two different Orai1 siRNAs sup-
pressed store-operated Ca
2+ entry, while knock down of Orai2
and Orai3 had no effect (Figure 1A, Figure S5). A third Orai1
siRNA was investigated, but it failed to have any effect on the
expression of Orai1 (Figure S3), and so it acted as a negative
control (Orai1 si.negative). Because the two active Orai1
siRNAs may have had off-target effects, rescue experiments
were performed using wild-type Orai1 cDNA, which had no
effect on its own but recovered the Ca
2+ entry that was sup-
pressed by Orai1 siRNA (Figure 1B). Ca
2+ entry was also sup-
pressed by the R91W dominant-negative mutant form of
Orai1 (Derler et al., 2009) (Figure 1A, Figure S5). The data
support the hypothesis that Orai1 is functionally important
for Ca
2+ entry evoked by thapsigargin and suggest that CRAC
channels are present.
Orai1 function in Ca
2+ entry evoked by PDGF
PDGF is an important physiological stimulant of VSMCs that
causes Ca
2+ release. Direct application of PDGF in Ca
2+-
containing extracellular solution evoked a rise in intracellular
Ca
2+ that had rapid onset followed by decay towards a plateau
phase of Ca
2+ entry (Figure 1C). Knock down of Orai1 had no
effect on the initial rise in Ca
2+ but suppressed the Ca
2+- entry
(Figure 1C, D). The data suggest that PDGF-evoked Ca
2+ entry
depends substantially on Orai1.
Potent and speciﬁc chemical inhibition of
Ca
2+ entry
With studies of ion channels, it is helpful to have a potent
and speciﬁc blocker that is easy to use and applicable to a
range of assays. Therefore, we investigated if a CRAC channel
blocker has effect on Ca
2+ entry in VSMCs. The blocker tested
was S66, which has previously been reported to speciﬁcally
inhibit CRAC-related signals in immune cells with an IC50 of
1.4–3.0 mM (Ng et al., 2008; Di Sabatino et al., 2009) whether
applied before or after store depletion (Ng et al., 2008). It was
observed that the Ca
2+ entry occurring upon returning Ca
2+ to
the medium (the add-back signal) in store-depleted VSMCs
was strongly suppressed by S66 (Figure 2A). Unexpectedly,
S66 had high potency, inhibiting the Ca
2+ entry signal with
an IC50 of 26 or 43 nM depending on whether the maximum
or rate-of-rise Ca
2+ signal was used (Figure 2B). We therefore
made a direct comparison with human leucocytes using the
same assay conditions. Consistent with previous reports, the
leucocyte Ca
2+ entry was much less sensitive, giving an IC50 of
1.76 mM (Figure 2B). The effect of S66 on VSMCs occurred
relatively rapidly, with a time constant of ~7 s (Figure 2C, D).
S66 had no effect on the initial rise in Ca
2+ evoked by PDGF
but suppressed the plateau phase of Ca
2+ entry (Figure 3A, B).
Consistent with the lack of effect on Ca
2+ release, in the
absence of extracellular Ca
2+, PDGF evoked a transient rise in
intracellular Ca
2+ that was unaffected by S66 (Figure 3C, D).
Similar observations were made when ATP was the receptor
agonist used to evoke Ca
2+ release and Ca
2+ entry (Figure 3E,
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for store-operated Ca
2+ entry in human VSMCs, and that the
potency is almost two orders of magnitude greater compared
with immune cells.
Lack of effect of S66 on endogenous or
overexpressed TRPC channels
The above data suggest that S66 has speciﬁcity because it
lacked effect on the PDGF receptor or Ca
2+ release mecha-
nism. To further investigate the speciﬁcity, we tested
S66 against the Ca
2+ signal evoked by the endogenous
oxidized phospholipid PGPC (1-palmitoyl-2-glutaroyl-
phosphatidylcholine) (Al-Shawaf et al., 2010). Although
PGPC evokes a transient rise in intracellular Ca
2+, this effect
is not accounted for by Ca
2+ release but by Ca
2+ entry medi-
ated by TRPC1/5-containing channels (Al-Shawaf et al.,
2010). The PGPC-evoked Ca
2+ signal was completely unaf-
fected by S66 at the high concentration of 5 mM (Figure 4A,
B). We also investigated human TRPC5 conditionally over-
expressed in HEK 293 cells and stimulated by the lan-
thanide ion, gadolinium (Zeng et al., 2004); this signal was
also unaffected by S66 (Figure 4C). The data suggest that
S66 does not inhibit endogenous TRPC1/5 or overexpressed
TRPC5 channels.
Lack of effect of S66 on STIM1 clustering
A widely accepted mechanism for coupling of depleted Ca
2+
stores to plasma membrane store-operated Ca
2+ channels
is the clustering of STIM1 proteins in sarcoendoplasmic
reticulum membranes and the subsequent interaction with
plasma membrane channels (Cahalan, 2009). Therefore, the
effects of S66 on the clustering of STIM1 were investigated.
YFP-tagged STIM1 was expressed in VSMCs and observed by
ﬂuorescence microscopy. In the absence of store depletion,
STIM1 showed the expected microtubule-like localization
pattern (Figure 5A), consistent with it binding a plus-end
microtubule tracking protein (Cahalan, 2009). Also, as
expected, application of thapsigargin caused striking
re-arrangement of STIM1 into clusters (Figure 5B). S66,
however, had no effect on the clustering process (Figure 5C).
These data suggest that S66 does not act by inhibiting store
depletion, its sensing by STIM1 or the subsequent
re-arrangements of STIM1 that are considered to be necessary
for activation of store-operated channels.
Lack of effect of S66 on store-operated
non-selective cationic current
In human saphenous vein VSMCs, there is also a large non-
selective cationic current that is evoked by thapsigargin and
Figure 1
Effect of Orai1 knock down on Ca2+ entry of human saphenous vein vascular smooth muscle cells (VSMCs). (A, B) Prior to recording Ca2+ signals,
VSMCs were divided into paired groups and transfected with control (siRNA ctrls, scrambled siRNA) or test siRNA (e.g. Orai1 si.1), or control DNA
(vector) or vector expressing R91W-Orai1 or Orai1 (wild-type) cDNA. Although only one control column is shown in each graph, each test group
had its own control, and the data were normalized (Norm.) to that control. NS indicates no signiﬁcant difference compared with the matched
control data. The ‘Orai1 si.negative’ was generated for the purpose of suppressing Orai1 expression but it failed to have any effect on the
expression and so was used as a negative control. For Ca
2+ recording, VSMCs were pretreated with 1 mM thapsigargin in Ca
2+-free bath solution
for 30 min and exposed to 0.2 mM extracellular Ca
2+ as indicated. (A) Mean normalized (Norm.) data for experiments of the type illustrated in
Figure S5 (n/N = 3–4/48–64). Raw mean control fura-2 ratio values for each of the seven groups were 0.55, 0.90, 0.54, 0.70, 0.56 and 0.57 (left
to right). (B) Rescue of Ca
2+ entry in Orai1 knock down cells by Orai1 cDNA (n/N = 3/48). Raw mean control fura-2 ratio values for each of the
three groups were 0.50, 0.48 and 0.45 (left to right). (C) Typical Ca
2+ responses to 100 ng·mL
-1 PDGF in the presence of extracellular 1.5 mM
Ca
2+ after transfection with control (ctrl) or Orai1 siRNA 1 (N = 12 each). (D) Mean data for the type of experiment illustrated in (C) (n/N = 3/30).
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investigators have observed a similar ionic current in
response to store depletion (Trepakova et al., 2001; Sweeney
et al., 2002). This ionic current in human saphenous vein
VSMCs was completely unaffected by S66 at 5 mM (Figure 6A–
C). These data suggest that the action of S66 is not general for
all types of store-operated channel.
Lack of effect of S66 on phenylephrine-evoked
contraction
The possible effect of S66 on the contractile function of
VSMCs was investigated by making isometric tension record-
ings from freshly-isolated aortic rings of the mouse. Phenyle-
phrine was used as an a1-adrenoceptor agonist to evoke
contraction (Figure 7A). S66 (5 mM) had no effect on the
evoked contraction whether applied before (Figure 7A, B) or
acutely after phenylephrine (Figure 7B). Phenylephrine-
evoked contraction did, nevertheless, depend substantially
on Ca
2+ entry (Figure 7B). These data further suggest the
speciﬁcity of S66, as it had no effect on the a1-adrenoceptor-
mediated signalling mechanisms, Ca
2+ handling in contrac-
tile cells or the contractile machinery.
Potent inhibition of VSMC migration by S66
Because of the high potency and selectivity of S66, we used it
to investigate the relevance of the Ca
2+ entry mechanism to
VSMC migration and proliferation. Cell migration was
equally suppressed by 0.1 and 5 mM S66 (Figure 8A, Fig-
ure S7), suggesting high potency against this cellular param-
eter that is similar to that observed against Ca
2+ entry.
Modest effect of S66 on VSMC proliferation
and lack of effect on cell viability
The saphenous vein VSMCs doubled in number over a period
of ~7 days in the presence of serum (data not shown),
whereas in the absence of serum the cell number declined
relative to the serum group (Figure 8B). The cell count in the
presence of serum was quantiﬁed over 4 days in the presence
of the S66 solvent (vehicle control) or different concentra-
tions of S66. The cell counts were normalized to the vehicle
controls at the speciﬁed time points (Figure 8B). At days 1 and
2, the cell count was unaffected by S66 and, similarly, con-
centrations of S66 below 1 mM lacked effects on the cell
counts at days 3 and 4 (Figure 8B). There were, however,
inhibitory effects of 1 and 5 mM S66 at days 3 and 4
(Figure 8B). Cell death, as indicated by trypan blue uptake,
was small over these time periods in the presence of serum
and was not affected by 5 mM S66 (Figure 8C). The data
suggest that S66-sensitive Ca
2+ entry has a positive but rela-
tively modest effect on cell proliferation and no effect on cell
viability.
Figure 2
S66 inhibition of Ca
2+ add-back responses in store-depleted VSMCs. (A) Example of VSMC paired experiment showing inhibition by 5 mM S66 of
the Ca2+ entry signal observed when adding 0.2 mM Ca2+ to thapsigargin-treated cells (N = 10 each). (B) As for (A) but mean data for the
maximum (max.) Ca
2+ entry signal (n/N = 4/40) with a ﬁtted Hill equation (IC50 26 nM, slope 1.05). The rate of rise of the same Ca
2+ entry events
(rate) was also analysed, and the mean data (not shown but see Figure S6) were ﬁtted with a Hill equation (dotted curve, IC50 43 nM, slope 0.69).
Comparative maximum Ca
2+ entry data are shown for HL-60 cells, also with a ﬁtted Hill equation (IC50 1.76 mM, slope 1.0). (C) As for (A) but 5 mM
S66 or its vehicle were applied after add-back of 1.5 mM Ca
2+ (N = 10 each). (D) As for (C) but the mean difference between S66 and vehicle data
points (n = 3) with a ﬁtted single exponential function (smooth curve, t=7.01 s).
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S66 inhibition of Ca2+ entry evoked by physiological agonists. Recordings were made from VSMCs. (A) Intracellular Ca2+ measurement showing
responses to 100 ng·mL
-1 PDGF in 1.5 mM extracellular Ca
2+ and vehicle or 5 mM S66 (N = 32 each). (B) Mean data for the type of experiment
illustrated in (A) comparing the vehicle control and S66 (n/N = 3/72). (C, D) As for (A, B) but in the absence of extracellular Ca
2+ (n/N = 5/64)
and therefore showing Ca
2+ release only. (E, F) As for (A, B) but using 100 mM ATP instead of PDGF (n/N = 3/48).
Figure 4
Resistance of TRPC1/5 channels to S66. Recordings were made from VSMCs (A, B) or HEK 293 cells (C). (A) Intracellular Ca
2+ measurement
showing responses to 5 mM 1-palmitoyl-2-glutaroyl-phosphatidylcholine (PGPC) in 1.5 mM extracellular Ca
2+ and vehicle or 5 mM S66 (black
circles) (N = 16 for each). (B) As for (A) but mean data for the vehicle control and S66 (n/N = 3/64). (C) As for (A) but using HEK 293 cells with
overexpression of TRPC5 showing responses to 50 mM gadolinium (Gd3+) in the presence of vehicle or 5 mMS 6 6( N = 12, typical of n = 3).
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Orai1 siRNA
The data obtained with S66 suggested a relatively speciﬁc role
of the Ca
2+ entry channels in cell migration. It was therefore
investigated if knock-down of Orai1 with siRNA had a similar
effect (Figure 8D). Orai1 knock down had a strong inhibitory
effect on VSMC migration and no effect on cell proliferation
over 2 days (Figure 8D). The inhibition of cell migration was
quantitatively greater than that observed with S66
(Figure 8D; cf. Figure 8A). The data suggest that CRAC chan-
nels and Orai1 impact positively on VSMC migration, and
that Orai1 may not only contribute through the CRAC
channel mechanism.
Discussion and conclusions
These data support the hypothesis that Orai1 has a role in
Ca
2+ inﬂux evoked by store depletion in VSMCs and reveal a
chemical inhibitor of the CRAC channel that is a promising
tool for further investigation of the mechanism, showing
~100-fold selectivity for VSMCs over leucocytes. The chemi-
cal showed excellent speciﬁcity, lacking effects on PDGF
receptors, ATP receptors, Ca
2+ release, TRPC1/5 channel-
dependent Ca
2+ entry, STIM1 clustering, non-selective cat-
ionic current evoked by store depletion and the entire
mechanisms of a-adrenoceptor-mediated vascular contrac-
tion. In line with results from Orai1 knock-down experi-
ments, S66 suppressed VSMC migration, although not as
effectively as Orai1 knock down.
In addition to patent information (WO 2005/009954),
effects of S66 on CRAC channel activity in rat basophilic
leukaemia and Jurkat T cells have been reported in the scien-
tiﬁc literature (Ng et al., 2008; Di Sabatino et al., 2009). S66
was found to have speciﬁcity because it did not affect plasma
membrane Ca
2+ ATPase, inward rectiﬁer K
+ current, hippoc-
ampal synaptic transmission or radioligand binding to a
range of receptors and ion channels including the L-type Ca
2+
Figure 5
Resistance of STIM1 clustering to S66. The images all show VSMCs from the same batch transfected with plasmid expressing eYFP-STIM1 (green
colour). VSMCs were then exposed for 5 min to: (A) the solvent for thapsigargin (vehicle control 1); (B) 1 mM thapsigargin (TG) and the solvent
for S66 (vehicle control 2); or (C) 1 mM thapsigargin and 10 mM S66. The scale bar in (A) applies to all of the images. Data are representative of
two independent experiments on VSMCs from different patients.
Figure 6
Resistance of non-selective store-operated cationic current to S66. Recordings were made from VSMCs. (A) Example of ionic current evoked by
2 mM thapsigargin (TG), showing effects of 5 mM S66 and 50 mM lanthanum (La3+). (B) As for (A) but example current–voltage relationships (I–V)
for currents evoked by TG and then following the addition of S66. (C) As for (A) but mean data normalized to the current in the presence of TG
alone, showing the effect of S66 and La
3+ (n = 14 cells from 3 patients).
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Resistance of aortic contraction to S66. Recordings were made from mouse aorta. (A) Sequential isometric tension recordings from a ring of mouse
aorta showing responses to 1 mM phenylephrine (PE) in the presence of vehicle (DMSO, left panel) or 5 mM S66 (right panel). (B) Mean
phenylephrine-evoked contractions normalized to the vehicle control data (ctrl) for the acute (15 min) effect of 5 mM S66 (acute S66) and effect
of pretreatment and continuous application of 5 mM S66 (pre S66) (as in A). The effect of removing extracellular Ca
2+ is shown for comparison
(0 Ca
2+).
Figure 8
Effects of S66 on VSMC migration, proliferation and viability. (A, B) Mean data for S66 effects on cell migration (A) and cell count (B) as
percentages of their own vehicle controls (ctrls). (B) Cell count was measured in the presence of serum and various concentrations of S66 at 1,
2, 3 and 4 day time points (1–4 days) (symbols with error bars and connecting lines). The dashed horizontal lines are comparative mean data for
cell counts in serum-free conditions as percentages of their serum controls. (C) Mean numbers of cells that failed to exclude trypan blue (i.e.
non-viable cells) as a percentage of the total number of cells for the vehicle control (white bar) and S66 (black bar) groups at 3 and 4 days. (D)
Mean data for number of cells migrating in Boyden chambers (‘migrated’) and with trypan blue exclusion in the presence of serum over 2 days
(‘count at 2 days’). Data obtained after transfection with Orai1 siRNA (Orai1 si.1) or Orai1 negative siRNA (Orai1 si.-ve) were normalized to their
own scrambled siRNA controls (siRNA ctrls), even though only one control column is shown. (A, D) Raw mean migrated cell numbers in the
controls (ctrls) were 28.9 and 32.5 (for the 0.1 and 5 S66 groups) and 30.4 and 31.8 (for the Orai1 si.1 and Orai1 si.-ve groups). (A–D) Data are
from experiments performed at least twice with cells from at least four patients.
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not only expand the evidence for speciﬁcity but also show
that S66 has two orders of magnitude greater potency at the
CRAC mechanism in VSMCs. In conﬁrmation of prior obser-
vations, and under identical conditions to those used for the
VSMC recordings, we showed that the CRAC mechanism in
leucocytes is less sensitive to S66. The data suggest pharma-
cological opportunity and a fundamental difference between
the CRAC mechanisms of the vascular and immune cells,
even though Orai1 and STIM1 are involved in both cases.
The ionic current of Figure 6 has been previously
described as a non-selective cationic current evoked by
thapsigargin in saphenous vein smooth muscle cells and
inhibited partially by extracellular antibody targeted to
STIM1, suggesting the importance of plasma membrane
STIM1(Li et al., 2008). The lack of cationic selectivity of this
current, its large amplitude and relatively linear current–
voltage relationship suggest that it is not mediated by a
CRAC channel. Other investigators have observed similar
currents (Trepakova et al., 2001; Sweeney et al., 2002; Stiber
et al., 2008). We show here that the current in saphenous
vein smooth muscle cells is not sensitive to acute inhibition
by S66, further distinguishing it from the CRAC mechanism.
It might be expected that a CRAC channel current would
have been evident in our electrophysiology experiments, but
it was not observed, possibly because of the extremely small
size of the current, which was not detectable in rat smooth
muscle cells in the presence of extracellular calcium (Potier
et al., 2009).
Conﬂicting conclusions are reported about the contribu-
tions of TRPC channels to store-operated Ca
2+ entry in
VSMCs. Nevertheless, speciﬁcally in relation to human
saphenous vein VSMCs, our data consistently point to a role
of TRPC channels in the Ca
2+ add-back signal of thapsigargin-
treated cells, based on anti-TRPC1 blocking antibody, TRPC1/
4/5 RNA interference and dominant-negative mutant TRPC
experiments (Kumar et al., 2006; Li et al., 2008). The effects
have, nevertheless, been only partial (up to 40%). Therefore,
at least 60% of the Ca
2+ add-back signal would seem to have
been mediated by other mechanisms (i.e. non-TRPC1/4/5
mechanisms). These ﬁndings should be considered in the
context of the present study where we observed that S66 had
no effect on TRPC activity evoked by non-store depletion
mechanisms but inhibited store-operated Ca
2+ entry by about
90%. It seems therefore that there is a quantitative discrep-
ancy with the previous data based on disruption of TRPC
subunits. A reason for the discrepancy (i.e. of ~10% vs. ~40%
TRPC contribution) could be that the TRPC contribution to
the store-operated Ca
2+ add-back signal depends on CRAC
channel activity. If this is the case, the TRPC channels would
contribute to the Ca
2+ add-back signal only if the CRAC
channels were ﬁrst activated by store depletion and then the
CRAC channels stimulated the TRPC channels, perhaps via
Ca
2+ facilitation. This may be an over-simpliﬁcation,
however, because of compelling evidence that TRPC channels
are activated directly by store depletion due to physical cou-
pling with STIM1 (Zeng et al., 2008). Indeed, our immune-
precipitation and immune-staining results have supported
the conclusion that a pool of TRPC1 interacts with STIM1 in
saphenous vein smooth muscle cells (Li et al., 2008).
Although the relationship of TRPC channels to store deple-
tion remains puzzling, it is clear that such channels do not
require store depletion in order to be activated in VSMCs
(Al-Shawaf et al., 2010).
The mechanism of action of S66 on Ca
2+ entry is
unknown. It acts relatively rapidly and so may function as
an ion pore blocker of CRAC channels. Most simply, it
would have such an effect by binding directly to Orai1.
However, evidence to support such a hypothesis is lacking
and the common role of Orai1 in Ca
2+ entry of VSMCs and
immune cells, and yet differential potencies of S66 on these
cell types, argues against Orai1 as the target protein.
However, if Orai1 is not the target protein, we do not have
another clear candidate. Our data argue against S66 acting
through disruption of the STIM1 mechanism for store-to-
channel coupling (Figure 5) or as a general blocker of all
types of store-operated channel (Figure 6). It may interfere
with the physical coupling between STIM1 and Orai1, but it
is unclear why the VSMC Ca
2+ entry would be more potently
affected.
One of the curious results of the study was that Orai1
knock down inhibited VSMC migration by about 80%
whereas S66 inhibited it by only 40%. If Orai1 acted only as
a subunit of CRAC channels, the percentage inhibition would
be predicted to be similar or the effect of S66 may even be
anticipated to be greater because it is such a strong inhibitor
of the channels and siRNA knocks down the gene expression
rather than deleting it. One explanation could be that Orai1
has a role in cell migration in addition to those that occur via
the CRAC channel. However, additional evidence for such a
hypothesis is needed because the possibility that S66 becomes
less effective progressively in culture, either because of chemi-
cal modiﬁcation or desensitization at its receptor, was not
excluded.
In summary, the results of this study suggest the impor-
tance of Orai1 and CRAC channels as mediators of
thapsigargin-, PDGF- and ATP-evoked Ca
2+ entry in human
saphenous vein VSMCs and that this mechanism potentiates
migration of the cells but is not essential for migration. These
ﬁndings support the hypothesis that CRAC channels are
important in VSMCs, even though it has not, so far, been
possible to detect an associated ionic current (i.e. I-CRAC) in
physiological Ca
2+ conditions. The study also reveals an easy-
to-use small molecule inhibitor of the Ca
2+ entry mechanism
that has promising speciﬁcity and should be useful in further
studies of the mechanism in a wide range of experiments.
Perhaps most striking is the nanomolar potency of the inhibi-
tor and approximate 100-fold selectivity for VSMCs over
immune cells. This suggests that the CRAC channels of
VSMCs are fundamentally different from those of immune
cells, even though Orai1 and STIM1 are involved in both.
From a pharmacological perspective, it would seem worth-
while to consider chemicals such as S66 as potential thera-
peutic inhibitors of vascular remodelling without negative
implications for vascular tone or immune response.
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392 British Journal of Pharmacology (2011) 164 382–393Figure S1 Relevant gene expressions in human saphenous
vein VSMCs. (a) Typical gel showing PCR products for Orai1,
2 and 3 mRNAs with (+) but not without (–) reverse tran-
scriptase (RT) reaction. A DNA marker ladder is on the left. (b)
Using real-time RT-PCR quantiﬁcation, relative abundances
of the mRNAs encoding the indicated proteins (n = 3–4).
Figure S2 Example Ca
2+ add-back signals in human saphen-
ous vein VSMCs with and without store depletion and
showing comparison of effects of two chemically different
store depletion agents, thapsigargin (TG) and cyclopiazonic
acid (CPA). Intracellular Ca
2+ was measured in cells pretreated
(as indicated below) in Ca
2+-free bath solution for 30 min and
then exposed to 0.2 mM extracellular Ca
2+ as indicated by the
horizontal bar labelled ‘add-back’, except for one group of
cells where the Ca
2+ was not added back (0 Ca
2+). The pre-
treatments in addition to the Ca
2+-free solution were 1 mM
TG, 10 mMC P A ,1mM TG plus 10 mM CPA (TG + CPA), 0.2%
dimethylsulphoxide (DMSO) as the vehicle control for TG
and CPA, or no TG, CPA or DMSO (none).
Figure S3 Validation and speciﬁcity of siRNA knock down of
Orai expression. See Table S1 for annotations. (a) Validation
of knock down, showing relative abundances of Orai1, 2 and
3 mRNAs after transfection of vascular smooth muscle cells
with Orai1, 2 and 3 siRNAs as indicated (n/N = 3/6). The
control was scrambled siRNA. (b) Validation of speciﬁcity,
showing lack of effect on the non-target mRNAs (as indi-
cated) after transfection of vascular smooth muscle cells with
the indicated siRNAs (n/N = 2–3/4–6).
Figure S4 Endogenous Orai1 protein detection and knock
down in human saphenous vein VSMCs. Western blot for
lysates from cells transfected with control (scrambled) siRNA
(siRNA ctrl) or Orai1 siRNA 1 (Orai1 si.1). The blot was probed
with anti-Orai1 antibody (upper panel) and anti-b-actin anti-
body (lower panel). The predicted protein mass of Orai1 is
33 kDa (arrow).
Figure S5 Typical original traces for the mean data shown in
Figure 1A. For N = 16 per individual experiment, intracellular
Ca
2+ measurements from VSMCs pretreated with 1 mM thapsi-
gargin in Ca
2+-free bath solution for 30 min and then exposed
to 0.2 mM extracellular Ca
2+ as indicated by the horizontal
bars: comparing control (scrambled) siRNA with Orai1 siRNA
1( a), Orai2 siRNA (b), Orai3 siRNA (c), Orai2 and Orai3
siRNAs (d) and Orai1 siRNA 2 (e); and comparing DNA vector
with Orai1 R91W mutant (dominant negative) (f).
Figure S6 In support of the dotted curve in Figure 2B, the
graph shows the mean rate of rise data points without nor-
malization and with the ﬁtted Hill equation. The y-axis is the
linear slope of the initial rate of rise of the fura-2 ﬂuorescence
after extracellular Ca
2+ was added to the medium.
Figure S7 Original data for VSMC migration assays. Typical
bright-ﬁeld images of human saphenous vein VSMCs that
had moved through pores in the polycarbonate membrane
for vehicle control (ctrl) and 1 mM S66. A cell is indicated by
a white arrow and a pore by a black arrow.
Table SI PCR primer pairs (F, forward direction; R, reverse
direction), PCR amplicon sizes, and siRNA probes sequences.
The ‘Orai1 si.negative’ was generated for the purpose of sup-
pressing Orai1 expression, but it failed to have any effect on
the expression and so was used as a negative control
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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